Nuvance (Immunex)
Lange, R.W.
Idrugs the Investigational Drugs Journal 2(5): 454-459
1999
ISSN/ISBN: 1369-7056 PMID: 16155848 Document Number: 505902
Immunex is carrying out worldwide phase II trials on a genetically-engineered soluble interleukin-4 receptor (IL-4R, Nuvance), administered as a nebulized liquid, for the potential treatment of allergic asthma. IL-4R may also be of use in the treatment of organ transplant rejection, graft versus host disease, allergy and infectious disease.